NoSarC - Norwegian Sarcoma Consortium
The NoSarC project, initiated in 2014, has inspired the Norwegian sarcoma environment, and stimulated the interest also for clinical research.
This interdisciplinary consortium of academic scientists and clinicians, representing all health regions grew out of the Norwegian Cancer Genomics Consortium. With the support from the Cancer Society, Helse Sør-Øst, The Research Council of Norway, and private funds, NoSarC is accruing an internationally unique biobank. It contains material from several annual population-based cohorts of Norwegian sarcoma patients. The value of our biobank has already been proven through international collaborations.
The NoSarC project has several objectives:
- Collection of a population-based biobank of tumor, blood, plasma and serum samples from sarcoma patients in all health regions of Norway, resulting in approximately 600 samples so far
- Next generation sequencing (NGS) analysis of all genes to identify possibly targetable mutated driver mechanisms and possible genetic predisposing factors
- Establishing in vivo and in vitro models from the most aggressive tumors
- Preclinical investigations to determine efficacy of available drugs in sarcoma cells in vitro, based on targets found by NGS analysis
- Medium-throughput drug screens to identify drugs with in vitro efficacy against sarcoma cells
- In vivo validation of promising drugs in sarcoma xenograft models
- Initiation of small-scale national and international clinical trials to evaluate the efficacy of new drugs in sarcoma patients